ClinicalTrials.gg
Not yet recruitingNCT07623824Updated Jun 3, 2026

A Phase III Clinical Trial to Evaluate the Efficacy and Safety of Octreotide Long-acting Injection in Patients With Acromegaly

A Phase 3 interventional study of SYHX2008 and Sandostatin LAR® in Diagnosed With Acromegaly, Currently in the Active Stage of the Disease, sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing octreotide in Acromegaly — 1 open to participants now, 1 under way, 1 of them phase 3. Octreotide · Acromegaly.

Planned enrollment
3rd of 25
154 · median 56
Started
2026
the only one that year
Phase 3
12 of 25
1 open now
Registered
25th of 25
by date
Lead sponsor
2 of 25
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Among the 25 studies testing octreotide in Acromegaly, this one is the 3rd largest by planned enrollment, is the only one that started in 2026, is one of 12 in phase 3, and was the 25th registered.

Acromegaly

202 studies on the registry are indexed under Acromegaly; 19 are open to participants now.

Browse Acromegaly studies →

Open to participants now

1 of the 25 studies testing octreotide in Acromegaly is open now.

About octreotide

Octreotide: first FDA approval 1988 (SANDOSTATIN), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 14 Acromegaly studies recruiting now, 7 (50%) set no upper age limit and 5 (36%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing octreotide in Acromegaly, or all of them as a file.
02

Study summary

he purpose of this study is to evaluate the efficacy and safety of SYHX2008 injection in in patients with acromegaly.

Read the detailed description

This study is a randomized, parallel, open-label, multicenter, positive-controlled, superiority-designed Phase III clinical study evaluating the efficacy and safety of octreotide long-acting injection in patients with acromegaly. The purpose of this study is to evaluate the efficacy and safety of SYHX2008 injection in treating acromegaly. Patients will be randomized to SYHX2008 cohort or Octreotide Microspheres(Sandostatin LAR®) cohort. A total of 154 participants are expected to be enrolled. The study will consist of a maximum 4-week screening/Baseline period, followed by 28-week treatment period.

03

Conditions studied

  • Diagnosed With Acromegaly, Currently in the Active Stage of the Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants aged 18 to 80 years (including boundary values)
  • Diagnosed with acromegaly, currently in the active stage of the disease (for patients who have not undergone pituitary tumor surgery before, MRI shows a pituitary mass, fasting GH ≥ 2.5 ng/mL and IGF-1 index ≥ 1.3; for patients who have undergone pituitary tumor surgery, fasting GH ≥ 2.5 ng/mL and IGF-1 index ≥ 1.3);

Exclusion criteria

Exclusion Criteria:

  • Have received pituitary radiotherapy within the 5 years prior to screening
  • Have undergone major surgery (including pituitary surgery) within 6 months prior to screening or are expected to require surgery (including pituitary surgery) or radiotherapy during the study period
  • Within three months before the screening, participants received drugs such as long-acting lanretide, long-acting octreotide, pervesomone, and cabergoline, or traditional Chinese medicines for treating acromegaly. Receive bromocriptine within one month before screening; Received short-acting octreotide or lanretide short-acting preparations for treatment within 7 days before screening; Or have received any other drug within 30 days before screening or within 5 half-lives (whichever is longer)
  • Previous failure to respond to octreotide or lantreotide monotherapy (defined as: after at least 3 months of treatment with octreotide microspheres ≥30 mg or lantreotide ≥120 mg, or after at least 3 months of treatment with parietide microspheres ≥40 mg, random GH ≥2.5 ng/mL and/or IGF-1 index ≥1.3) or history of intolerance.
  • Participants with obvious visual field defects caused by optic chiasm compression and requiring surgical intervention
  • >8.5%
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
154 participants (estimated)

Study arms

  • Experimental
    SYHX2008

    SYHX2008

    Drug: SYHX2008

  • Experimental
    Sandostatin LAR®

    Sandostatin LAR®

    Drug: Sandostatin LAR®

Interventions

  • The patients will accept SYHX2008 injection by subcutaneous administration.A treatment period of 28 weeks.

  • The patients will accept Sandostatin LAR@ by intra-muscular administration.A treatment period of 28 weeks.

06

What researchers measure

Primary outcomes

  1. The proportion of patients with an IGF-1 index ≤ 1.0

    insulin-like growth factor-1 within the normal range after adjustment for age and gender, where IGF-1 index = IGF-1 value/ULN, and ULN is the upper limit of the normal reference range

    Time frame: Week 28

Secondary outcomes

  1. The proportion of patients with fasting GH less than 2.5 ng/mL and IGF-1 index less than or equal to 1.0

    Time frame: weeks 4、8、12、16、20、24、28

  2. The proportion of patients with GH less than 1.0 ng/mL and IGF-1 index less than or equal to 1.0

    Time frame: weeks 4、8、12、16、20、24、28

  3. The proportion of patients with fasting GH < 1.0 ng/mL

    Time frame: Weeks 4、8、12、16、20、24、28

  4. The proportion of patients with fasting GH<2.5 ng/mL

    Time frame: Weeks 4、8、12、16、20、24、28

  5. The proportion of patients with an IGF-1 index ≤ 1.0

    insulin-like growth factor-1 within the normal range after adjustment for age and gender, where IGF-1 index = IGF-1 value/ULN, and ULN is the upper limit of the normal reference range

    Time frame: Weeks 4、8、12、16、20、24

  6. The rate of change in the volume of the pituitary tumor from the baseline

    Time frame: Weeks 28

  7. The change in the total PASQ score from the baseline

    Evaluation of effect on was assessed using Patient Assessed Acromegaly Symptom Question ( PASQ ), an acromegaly-specific quality of life instrument.

    Time frame: Weeks 12、28

  8. The change in the total AcroQoL score from the baseline

    Evaluation of effect was assessed using Acromegaly Quality of Life Questionnaire(AcroQoL), an acromegaly-specific quality of life instrument.

    Time frame: Weeks 12、28

  9. The proportion of patients with fasting GH decreased by ≥50% compared to the baseline

    Time frame: Weeks 4、8、12、16、20、24、28

  10. The proportion of patients whose IGF-1 index decreased by ≥50% compared with the baseline

    Time frame: Weeks 4、8、12、16、20、24、28

  11. Percentage changes in fasting GH from baseline

    Time frame: Weeks 4、8、12、16、20、24、28

  12. Percentage changes in IGF-1 from baseline

    Time frame: Weeks 4、8、12、16、20、24、28

  13. Incidence of adverse events (AE)

    Proportion of subjects with adverse events (AEs) within Weeks 28

    Time frame: From the signing of informed consent up to 28 Weeks after the first dose

  14. The concentration of octreotide

    The concentration of octreotide in the plasma of patients with acromegaly after administration of SYHX2008 injection and Sandostatin LAR®

    Time frame: From the signing of informed consent up to 28 Weeks afterthe first dose

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2026; primary completion for Jul 2029, 38 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2026
First posted
Jun 3, 2026
StartEst.
May 31, 2026
Primary completionEst.
Jul 31, 2029
CompletionEst.
Dec 30, 2029
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07623824
Responsible party
Sponsor
First posted
Jun 3, 2026
Start date
May 31, 2026 (estimated)
Primary completion
Jul 31, 2029 (estimated)
Completion
Dec 30, 2029 (estimated)
Last update
Jun 3, 2026

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
+86311-69085587

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: SYHX2008 · Octreotide

Start the discussion